文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性患者接受阿柏西普玻璃体腔注射后12周内早期谱域光学相干断层扫描变化评估:法国多中心START研究

ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Multicenter French Study (START).
PubMed 文献 · Retina · 2021-01-01

这项前瞻性、开放标签、单臂、多中心研究纳入50例抗VEGF初治的新生血管性年龄相关性黄斑变性患者,接受3次每月一次玻璃体腔注射阿柏西普2 mg。12周时34.0%(17/50)患者达到干性SD-OCT,黄斑中心厚度从基线463.2 ± 184.3 µm显著降至288.9 ± 76.8 µm(P < 0.0001),最佳矫正视力从61.0 ± 16.0个字母显著提高至66.6 ± 19.0个字母(P = 0.0006)。结论认为解剖和功能结局在12周研究期间改善,所有结局变量在第三次注射后达峰。

要点

  • 抗VEGF初治nAMD患者接受3次每月阿柏西普2 mg注射后,12周时34.0%达到干性SD-OCT。
  • 黄斑中心厚度从基线463.2 ± 184.3 µm显著降至12周288.9 ± 76.8 µm(P < 0.0001)。
  • 最佳矫正视力从基线61.0 ± 16.0个字母显著提高至12周66.6 ± 19.0个字母(P = 0.0006)。

核心结论

  • nAMD患者接受阿柏西普负荷期治疗后12周内解剖和功能结局改善。
  • 所有结局变量在第三次阿柏西普注射后达峰,支持3次初始剂量的获益。

研究设计与样本

  • 前瞻性、开放标签、单臂、多中心研究,纳入抗VEGF初治的新生血管性年龄相关性黄斑变性患者。
  • 患者接受三次每月一次玻璃体腔注射阿柏西普2 mg,评估12周内早期SD-OCT变化。
  • 共研究50例患者的50只眼。
  • 主要结局为12周时干性SD-OCT的患者比例,干性SD-OCT定义为无视网膜内水肿、视网膜内囊肿、视网膜下液和视网膜色素上皮下液。

主要发现

  • 12周时34.0%(17/50)患者达到干性SD-OCT。
  • 所有其他SD-OCT参数均观察到显著降低。
  • 平均黄斑中心厚度从基线463.2 ± 184.3 µm显著降至12周288.9 ± 76.8 µm(P < 0.0001)。
  • 平均最佳矫正视力从基线61.0 ± 16.0个字母显著提高至12周66.6 ± 19.0个字母(P = 0.0006)。

关键数值与推荐

  • 干性SD-OCT定义为无视网膜内水肿、视网膜内囊肿、视网膜下液和视网膜色素上皮下液。
  • 12周时干性SD-OCT比例为34.0%(17/50)。
  • 黄斑中心厚度12周较基线变化P < 0.0001。
  • 最佳矫正视力12周较基线变化P = 0.0006。

临床怎么用

  • 对于抗VEGF初治的nAMD患者,阿柏西普3次每月负荷剂量可在12周内改善解剖和功能结局。
  • 治疗12周时仅约三分之一患者达到干性SD-OCT,提示部分患者仍需进一步治疗或监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess early changes in spectral-domain optical coherence tomography during the loading phase with intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration. METHODS: In this prospective, open-label, single-arm, multicenter study, patients with neovascular age-related macular degeneration, who were antivascular endothelial growth factor treatment-naïve, received three monthly initial doses of intravitreal aflibercept 2 mg. The primary outcome was the proportion of patients with dry spectral-domain optical coherence tomography at 12 weeks, defined as an absence of intraretinal edema, intraretinal cysts, subretinal fluid, and subretinal pigment epithelium fluid. RESULTS: Fifty eyes of 50 patients were investigated. At 12 weeks, 34.0% (17/50) had dry spectral-domain optical coherence tomography. Marked reductions were observed for all other spectral-domain optical coherence tomography parameters. The mean macular central thickness fell significantly from 463.2 ± 184.3 µm at baseline to 288.9 ± 76.8 µm at Week 12 (P < 0.0001). The mean best-corrected visual acuity also improved significantly from 61.0 ± 16.0 letters at baseline to 66.6 ± 19.0 letters at Week 12 (P = 0.0006). CONCLUSION: The anatomic and functional outcomes improved over the 12-week study period. All outcome variables peaked after the third aflibercept injection, confirming the benefit of three initial doses.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Korobelnik JF, Souied EH, Oubraham H, et al. ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Multicenter French Study (START). Retina. 2021. PMID: 33600134. doi:10.1097/IAE.0000000000002910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。